EndoZyme® - Enhanced Recombinant Factor C (rFC) Endotoxin Assay
Hyglos is today pleased to announce the commercial launch of EndoZyme®, a homogeneous fluorescence microplate assay using recombinant Factor C derived from horseshoe crab, for measuring endotoxin(Lipopolysaccharides, LPS) in pharmaceuticals, biologics and medical equipment.
Taking up on the pioneering work published by the Japanese scientists around Prof. Sadaaki Iwanaga, the test developers at Hyglos have been able to finalize an improved recombinant Factor C (rFC) assay.
Recombinant factor C, which is the essential part of EndoZyme®, is the endotoxin-specific principal receptor in the LAL enzyme cascade. In the assay recombinant Factor C is activated by any endotoxin present in the sample, recombinant Factor C enzymatically cleaves a synthetic substrate resulting in a fluorescence signal.
EndoZyme® at a glance:
- Improved sensitivity and measurement range 0.005 EU/ml to 50 EU/ml
- Excellent correlation to LAL
- No false-positive glucan reaction due to endotoxin-specific recombinant technology
- Reliability and lot-to-lot consistency
- No animal material, therefore saving the diminishing horseshoe crab population
Date Published: January 21, 2013
Source article link: Hyglos GMBH » company contact details
12th Annual PDA Global Conference on Pharmaceutical Microbiology
Data Integrity for Endotoxin Testing – New FAQs Released to the QC Insider™ Toolbox
Lonza Unveils Agenda for 3rd Annual Global Endotoxin Testing Summit
3rd Annual Charles River QC Micro Workshop: 18 – 21, Sept 2017
White Paper: Low Endotoxin Recovery - Beyond the Controversy